HK1212973A1 - 壞死性雕亡的小分子抑制劑 - Google Patents

壞死性雕亡的小分子抑制劑 Download PDF

Info

Publication number
HK1212973A1
HK1212973A1 HK16100821.7A HK16100821A HK1212973A1 HK 1212973 A1 HK1212973 A1 HK 1212973A1 HK 16100821 A HK16100821 A HK 16100821A HK 1212973 A1 HK1212973 A1 HK 1212973A1
Authority
HK
Hong Kong
Prior art keywords
optionally substituted
compound
pharmaceutically acceptable
cycloalkyl
solvate
Prior art date
Application number
HK16100821.7A
Other languages
English (en)
Chinese (zh)
Inventor
Yuan Junying
S. Hsu Emily
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Publication of HK1212973A1 publication Critical patent/HK1212973A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C07C35/37—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed system having three rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/38—Alcohols containing six-membered aromatic rings and other rings and having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
HK16100821.7A 2008-12-23 2016-01-26 壞死性雕亡的小分子抑制劑 HK1212973A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14061508P 2008-12-23 2008-12-23
US61/140615 2008-12-23

Publications (1)

Publication Number Publication Date
HK1212973A1 true HK1212973A1 (zh) 2016-06-24

Family

ID=42288162

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16100821.7A HK1212973A1 (zh) 2008-12-23 2016-01-26 壞死性雕亡的小分子抑制劑
HK16111463.7A HK1223272A1 (en) 2008-12-23 2016-09-30 Small molecule inhibitors of necroptosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16111463.7A HK1223272A1 (en) 2008-12-23 2016-09-30 Small molecule inhibitors of necroptosis

Country Status (9)

Country Link
US (4) US20120122889A1 (cg-RX-API-DMAC7.html)
EP (2) EP2381775A4 (cg-RX-API-DMAC7.html)
JP (2) JP2012513481A (cg-RX-API-DMAC7.html)
CN (2) CN104803986A (cg-RX-API-DMAC7.html)
AU (2) AU2009329879A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0923126A2 (cg-RX-API-DMAC7.html)
CA (1) CA2772760A1 (cg-RX-API-DMAC7.html)
HK (2) HK1212973A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010075561A1 (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2567135T3 (es) 2003-08-29 2016-04-20 The Brigham And Women's Hospital, Inc. Derivados de hidantoína como inhibidores de necrosis celular
EP3034494A1 (en) 2007-08-15 2016-06-22 President and Fellows of Harvard College Heterocyclic inhibitors of necroptosis
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
EP2381775A4 (en) 2008-12-23 2012-08-15 Harvard College INHIBITORS OF NECROPTOSIS OF SMALL MOLECULAR SIZE
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
IT1401146B1 (it) 2010-07-27 2013-07-12 Gnosis Spa Composizione comprendente shellac e/o un suo sale e sodio amido glicolato
TW201307347A (zh) 2010-11-01 2013-02-16 Arqule Inc 經取代苯並－咪唑並－吡啶並－二氮呯化合物
WO2012125544A2 (en) 2011-03-11 2012-09-20 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
KR101410332B1 (ko) 2012-02-29 2014-06-24 코아스템(주) 중간엽 기질세포 배양용 항산화 조성물 및 이의 용도
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
TWI648273B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
JP2016514693A (ja) 2013-03-15 2016-05-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ハイブリッド型ネクロトーシス阻害剤
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
CN103396376B (zh) * 2013-07-31 2016-08-10 杨文茂 一种抗菌抗癌活性化合物
JP6307088B2 (ja) * 2013-10-23 2018-04-04 中外製薬株式会社 キナゾリノンおよびイソキノリノン誘導体
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
AU2015360291A1 (en) 2014-12-11 2017-07-13 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
CN107108467B (zh) * 2014-12-24 2022-08-19 北京生命科学研究所 细胞坏死抑制剂
CN107108492B (zh) * 2014-12-24 2021-03-19 北京生命科学研究所 细胞坏死抑制剂
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン
US9938300B2 (en) 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016133888A1 (en) * 2015-02-16 2016-08-25 Biota Pharmaceuticals, Inc. Compounds for treating respiratory syncytial virus infections
DE102015212208A1 (de) 2015-04-24 2016-10-27 Ihp Gmbh-Innovations For High Performance Microelectronics / Leibniz-Institut Für Innovative Mikroelektronik Hochgeschwindigkeits-Germanium-PIN-Fotodiode
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
HK1255074A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
CA3052767A1 (en) 2017-02-27 2018-08-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
WO2019133992A1 (en) 2017-12-31 2019-07-04 Evergreen Biosciences Compositions for cryopreservation and methods of use thereof
CN109078187B (zh) * 2018-08-02 2021-04-20 中国人民解放军第四军医大学 胰腺GnIH受体功能调节剂制备治疗2型糖尿病药物的应用
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
CN113302183A (zh) * 2018-11-20 2021-08-24 圣瑞诺有限公司 环脲
CN113272272B (zh) 2018-11-20 2023-04-07 圣瑞诺有限公司 Rip1抑制剂
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
AU2020391425A1 (en) 2019-11-26 2022-06-16 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease
JP7760530B2 (ja) * 2020-05-20 2025-10-27 シロナックス リミテッド． ピペラジン環状尿素類
EP4153571A4 (en) * 2020-05-20 2024-06-26 Sironax Ltd. RECEPTOR-INTERACTING PROTEIN-1 INHIBITORS WITH HETEROCYCLIC PIPERAZINAMIDE UREAS
US20230265094A1 (en) * 2020-06-12 2023-08-24 Merck Sharp & Dohme Llc Ripk1 inhibitors and methods of use
US20230227429A1 (en) * 2020-06-19 2023-07-20 Anaxis Pharma Pty Ltd Sulphonamide compounds

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577420A (en) * 1968-01-05 1971-05-04 Pfizer Certain 4-aminofuro(2,3-d)pyrimidines
BE789948A (fr) 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
JPS5113156B2 (cg-RX-API-DMAC7.html) 1972-10-21 1976-04-26
US4016037A (en) 1975-10-15 1977-04-05 Ajinomoto Co., Inc. Method for producing L-amino acid
US4110536A (en) * 1977-04-18 1978-08-29 Miles Laboratories, Inc. Derivatives of 5-(indol-3-yl)hydantoin
DE2728523C2 (de) 1977-06-23 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 4-Methyl-1,2,3-thiadiazol-5-carbonsäure-(cyclohexylmethyl)-amid, Mittel mit herbizider und wachstumsregulatorischer Wirkung enthaltend diese Verbindung sowie Verfahren zu seiner Herstellung
JPS5810074B2 (ja) 1979-07-18 1983-02-24 味の素株式会社 新規微生物
GB2080803B (en) 1980-07-28 1984-01-18 Pfizer Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4332952A (en) 1980-07-28 1982-06-01 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
DE3567460D1 (en) 1984-06-07 1989-02-16 Pfizer Ltd Dihydropyridines
JPS6122081A (ja) 1984-07-10 1986-01-30 Mitsui Toatsu Chem Inc ヒダントイン化合物の製造法
DE3685626T2 (de) 1985-09-26 1993-01-28 Beckmann Research Inst Of The Sequenzierung von peptiden.
IE62214B1 (en) 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
WO1990004183A1 (en) 1988-10-07 1990-04-19 Commonwealth Scientific And Industrial Research Organisation Method for preparation of thiohydantoins and for protein sequence analysis
ATE94906T1 (de) 1989-01-02 1993-10-15 Ruetgerswerke Ag Verfahren zur herstellung von l-alphaaminos|uren.
JPH054910A (ja) 1990-07-31 1993-01-14 Nikka Chem Co Ltd 化粧料組成物
WO1992004045A1 (en) 1990-08-31 1992-03-19 Warner-Lambert Company Novel cholecystokinin antagonists, their preparation and therapeutic use
NZ242065A (en) 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
US5693643A (en) 1991-09-16 1997-12-02 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
CH683995A5 (fr) 1991-12-02 1994-06-30 Nestle Sa (Alcoxy-1-éthenyl)-2-pyrroline-1 et procédé de préparation d'acétyl-2-pyrroline-1.
CA2083891A1 (en) * 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
WO1996030393A1 (en) 1995-03-27 1996-10-03 Warner-Lambert Company A method for the synthesis of mixtures of compounds
US6166054A (en) 1995-03-31 2000-12-26 Nihon Nohyaku Co., Ltd. Agricultural and horticultural disease controller and a method for controlling the diseases
US6846839B1 (en) 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
FR2750862B1 (fr) * 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
DE69722019T2 (de) 1996-09-30 2003-11-27 Nihon Nohyaku Co., Ltd. 1,2,3-thiadiazol-derivate und ihre salze, mittel zur kontrolle von krankheiten in landwirtschaft und gartenbau und eine methode zu ihrer anwendung
US6355664B1 (en) * 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
CN1249748A (zh) 1997-03-03 2000-04-05 贝林格尔·英格海姆药物公司 用于治疗炎症疾病的小分子
ATE224643T1 (de) * 1997-05-08 2002-10-15 Aventis Cropscience Uk Ltd Verwendung von thienopyrimidinen als fungizide
EP0976326B1 (en) 1998-07-30 2003-05-02 Nihon Nohyaku Co., Ltd. Fungicidal composition containing a 1,2,3-tiadiazole derivative and its use
WO2001028493A2 (en) 1999-10-15 2001-04-26 President And Fellows Of Harvard College Small molecule inhibitors of necrosis
US6756394B1 (en) 1999-10-15 2004-06-29 President And Fellow Of Harvard College Small molecule inhibitors of necrosis
US6706766B2 (en) 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
US20030087949A1 (en) 2000-03-30 2003-05-08 Mikiko Sodeoka Indolylpyrrole derivatives and cell death inhibitors
US20020155172A1 (en) 2000-04-07 2002-10-24 Junying Yuan Methods and compounds for decreasing cell toxicity or death
GB0011071D0 (en) 2000-05-08 2000-06-28 Novartis Ag Organic compounds
DE10031390A1 (de) * 2000-07-03 2002-01-17 Knoll Ag Pyrimidinderivate und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie
JP2002105081A (ja) * 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
AU2002220241A1 (en) * 2000-12-01 2002-06-11 Iconix Pharmaceuticals, Inc. Parb inhibitors
JP4529338B2 (ja) 2001-03-08 2010-08-25 味の素株式会社 ヒダントイナーゼをコードするｄｎａ、ｎ−カルバミル−ｌ−アミノ酸ハイドロラーゼをコードするｄｎａ、組み換えｄｎａ、形質転換された細胞、タンパク質の製造方法および光学活性アミノ酸の製造方法
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
DE10150325A1 (de) 2001-10-15 2003-04-24 Degussa Verfahren zur Herstellung oder Beschichtung von Granulaten, Vorrichtung zur Durchführung des Verfahrens und hiernach erhältliche Granulate
EP1442039A1 (en) * 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
IL161940A0 (en) 2001-11-22 2005-11-20 Ono Pharmaceutical Co Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
JP3659224B2 (ja) 2001-12-26 2005-06-15 村田機械株式会社 インターネットファクシミリ装置
AU2002359359A1 (en) 2001-12-28 2003-07-24 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
GB0302671D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7320986B2 (en) 2003-03-07 2008-01-22 Abbott Labortories Fused tri and tetra-cyclic pyrazole kinase inhibitors
WO2004093871A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel methods for the treatment of cancer
CN1795187A (zh) * 2003-03-27 2006-06-28 兰肯瑙医学研究所 新型ido抑制剂及其使用方法
US7465739B2 (en) * 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
ES2567135T3 (es) * 2003-08-29 2016-04-20 The Brigham And Women's Hospital, Inc. Derivados de hidantoína como inhibidores de necrosis celular
WO2005028664A2 (en) 2003-09-17 2005-03-31 University Of Massachusetts Modulation of programmed necrosis
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
AU2005208938A1 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc Anti-viral therapeutics
EP1720857B1 (en) * 2004-02-19 2011-07-13 Bayer Schering Pharma Aktiengesellschaft Dihydropyridinone derivatives
CA2557541C (en) * 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Pyrimidine derivatives
WO2005115147A2 (en) 2004-05-18 2005-12-08 Merck & Co., Inc. Hiv reverse transcriptase inhibitors
SG155188A1 (en) 2004-07-30 2009-09-30 Exelixis Inc Pyrrole derivatives as pharmaceutical agents
EP1802634A2 (en) * 2004-10-20 2007-07-04 Compass Pharmaceuticals LLC Thiophens and their use as anti-tumor agents
CA2594662A1 (en) 2005-02-10 2006-08-17 Merck & Co., Inc. Mitotic kinesin inhibitors
CN101304976A (zh) * 2005-10-11 2008-11-12 因特蒙公司 病毒复制抑制剂
US20090022694A1 (en) * 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
JP2009518286A (ja) * 2005-11-01 2009-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしてのジヒドロイソインドロン
WO2007059905A2 (en) * 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
AU2006331754B9 (en) 2005-12-20 2013-07-11 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
AR056882A1 (es) 2006-02-01 2007-10-31 Bayer Cropscience Sa Derivados del fungicida n- cicloalquil- bencil- amida
CA2658223A1 (en) 2006-07-13 2008-01-17 4Sc Ag Benzopyranopyrazoles
AU2007307044B2 (en) 2006-10-10 2014-03-20 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
CN100430403C (zh) * 2006-10-13 2008-11-05 中国科学院上海有机化学研究所 3-芳基-5,6-取代噻吩并嘧啶-4-羰基-2-巯基乙腈、合成方法和用途
CA2670026A1 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterotricyclic metalloprotease inhibitors
JP2010528051A (ja) * 2007-05-23 2010-08-19 シガ・テクノロジーズ・インコーポレーテッド デング感染症の治療または予防のための抗ウイルス薬
EP3034494A1 (en) 2007-08-15 2016-06-22 President and Fellows of Harvard College Heterocyclic inhibitors of necroptosis
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2257555B1 (en) * 2008-03-03 2012-07-04 National Chemical Laboratory Thieno[2,3-d]-pyrimidine-4(3h)-one compounds with antifungal properties and process thereof
GB0810542D0 (en) 2008-06-09 2008-07-16 Element Six Production Pty Ltd Cubic boron nitride compact
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
EP2381775A4 (en) 2008-12-23 2012-08-15 Harvard College INHIBITORS OF NECROPTOSIS OF SMALL MOLECULAR SIZE
WO2014152182A1 (en) 2013-03-15 2014-09-25 President And Fellows Of Harvard College Deuterated heterocyclic inhibitors of necroptosis
JP2016514693A (ja) 2013-03-15 2016-05-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ハイブリッド型ネクロトーシス阻害剤
AU2015360291A1 (en) 2014-12-11 2017-07-13 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods

Also Published As

Publication number Publication date
JP2015061853A (ja) 2015-04-02
EP3000468A1 (en) 2016-03-30
US20140024657A1 (en) 2014-01-23
AU2016202262A1 (en) 2016-05-12
BRPI0923126A2 (pt) 2021-09-08
AU2009329879A1 (en) 2011-08-11
CN104803986A (zh) 2015-07-29
EP2381775A4 (en) 2012-08-15
CN102316735A (zh) 2012-01-11
US20120122889A1 (en) 2012-05-17
EP2381775A1 (en) 2011-11-02
WO2010075561A1 (en) 2010-07-01
CA2772760A1 (en) 2010-07-01
JP6178777B2 (ja) 2017-08-09
US20170305824A1 (en) 2017-10-26
HK1223272A1 (en) 2017-07-28
US9586880B2 (en) 2017-03-07
US20190135718A1 (en) 2019-05-09
JP2012513481A (ja) 2012-06-14

Similar Documents

Publication Publication Date Title
HK1212973A1 (zh) 壞死性雕亡的小分子抑制劑
JP5645663B2 (ja) ネクロトーシスのヘテロ環式抑制剤
WO2010075290A1 (en) Unsaturated heterocyclic inhibitors of necroptosis
AU2019233698B2 (en) Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents
CN100464742C (zh) NF-κB活化抑制剂
SK14522000A3 (sk) Heterocyklicky substituované amidy, ich príprava a použitie
WO2017012770A1 (en) Acid addition salts of filgotinib
EP3419981A1 (en) Combination therapies for treatment of spinal muscular atrophy
CN110551048A (zh) 一类sirt2抑制剂、其制备方法及用途
AU2023204968B2 (en) Novel isoindolinone derivative compounds as caspase inhibitors
CN113754649B (zh) 一类含二唑、三唑及吡唑结构单元的吲哚衍生物及其应用
CA3093984C (en) Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents
JP2010195688A (ja) Ｎｐｙｙ５受容体拮抗作用を有するアミド及びウレア誘導体
JPH04230361A (ja) ２−（アミノアルキル）−ピロールアルデヒド、その製造方法およびその用途